Market News

Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market 2018 Expected Vast Growth By 2026 Including Freelancers, Intake, Trials & Forecast By Application, Technologies

Methicillin-Resistant Staphylococcus Aureus (MRSA) is a type of staphylococcus aureus, which became resistant to methicillin, amoxicillin, penicillin, oxacillin, and other such commonly used antibiotics. Staphylococcus aureus harbors on the skin and nasal passage of about one third of the world population, which comprises around 33%, as per Centers for Disease Control and Prevention (CDC) review 2015. MRSA can be classified into two types, based on mode of infection – Hospital Associated MRSA Infection (HA-MRSA) or community-associated MRSA infections (CA-MRSA).

Request For Sample Copy of This Research Report:

Staphylococcus aureus leads to skin infections such as boils, pimples, impetigo, abscesses or certain life threatening conditions such as septicemia (blood poisoning), pneumonia (lung infection), osteomyelitis (bone infection), endocarditis (heart valve infection), urinary tract infection, and septic bursitis (formation of small fluid-filled sacs under the skin).
Growth of the methicillin-resistant staphylococcus aureus (MRSA) drug market is driven by increasing product pipeline and increasing adoption of organic and inorganic strategies by key market players.

Increasing number of pipeline products for the treatment of methicillin resistance staphylococcus aureus infection is expected to fuel growth of the Methicillin-Resistant Staphylococcus Aureus (MRSA) drug market during the forecast period. For instance, in 2014, Cubist Pharmaceuticals Inc., received US FDA approval for its new antibiotic, Sivextro, available in both the forms – injection as well as oral, to treat skin infection caused by gram positive bacteria including MRSA. Moreover, new route of administration are experimented by market players to treat MRSA infection. For instance, in 2018, Destiny Pharma received investigational new drug application from FDA for its new candidate, XF-73, a dicationic porphyrin molecule based nasal gel, to combat with post-surgical infections of methicillin-resistant Staphylococcus aureus (MRSA). These increasing number of product approvals is expected to aid in growth of the MRSA drugs market over the forecast period.

Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs Market – Competitor

Key market player in methicillin-resistant staphylococcus aureus (MRSA) drugs market are Basilea Pharmaceutica Ltd., Cubist Pharmaceuticals Inc., Melinta Therapeutics, Inc., Theravance Biopharma, Allergan, Merck & Co., Xellia Pharmaceuticals ApS (owned by Novo Holdings A/S), King Pharmaceuticals Inc. (a wholly owned subsidiary of Pfizer), and PF Prism C.V. Players in the market are focusing inorganic growth strategies in order to enhance its market share and remain competitive in the market. For instance, in 2017, Melinta Therapeutics, Inc., acquired the infectious disease business from The Medicines Company. The acquisition includes three marketed products, one of which is Orbactiv, an injectable MRSA drug.

Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs Market – Restraint

Growth of the methicillin-resistant staphylococcus aureus (MRSA) drugs market is expected to be hampered by growing bacterial resistance. Further patent expiration of currently existing drugs will lead to large revenue losses to key players due to introduction of low cost generic drugs. Declining patient burden further restrains growth of the methicillin-resistant staphylococcus aureus (MRSA) drugs market. According to Centers for Disease Control and Prevention (CDC) studies, hospital associated MRSA infection has declined up to 54% between 2005 and 2011. This can be attributed to increasing awareness for personal and public hygiene.

Moreover, funding programs by healthcare organization will also propel drug discovery and development program, in turn leading to growth of the MRSA drug market. For instance, in 2017, Cystic Fibrosis Foundation Therapeutics (CFFT)—a non-profit drug discovery and development arm of Cystic Fibrosis Foundation—awarded US$ 5 million to Savara Inc., a clinical-stage specialty pharmaceutical company, for the development of AeroVanc, vancomycin hydrochloride inhalation powder, intended to treat MRSA lung infection in individual with cystic fibrosis.

Click To Read More On Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market

TechnoBleak Media Inc. ( is an Independent Online News Portal intended to deliver news related to Apps, Technology, Startups, and Gadgets. It is run by writers and co-workers living in different parts of the world. We aim to create high-quality content for our readers who like to read business and technology news & updates. At TechnoBleak, we offer the latest news, breakthroughs, and analysis with emphasis on expert opinion and commentary from the Technology and Startups community.

Office Address:

TechBleak Media Inc.
501 Boylston Street,
Boston, MA 02116.

EMail: [email protected]